Your browser doesn't support javascript.
loading
Predicting HIV-1 Protease Cleavage Sites With Positive-Unlabeled Learning.
Li, Zhenfeng; Hu, Lun; Tang, Zehai; Zhao, Cheng.
Afiliación
  • Li Z; School of Computer Science and Technology, Wuhan University of Technology, Wuhan, China.
  • Hu L; Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Ürümqi, China.
  • Tang Z; School of Computer Science and Technology, Wuhan University of Technology, Wuhan, China.
  • Zhao C; School of Computer Science and Technology, Wuhan University of Technology, Wuhan, China.
Front Genet ; 12: 658078, 2021.
Article en En | MEDLINE | ID: mdl-33868387
Understanding the substrate specificity of HIV-1 protease plays an essential role in the prevention of HIV infection. A variety of computational models have thus been developed to predict substrate sites that are cleaved by HIV-1 protease, but most of them normally follow a supervised learning scheme to build classifiers by considering experimentally verified cleavable sites as positive samples and unknown sites as negative samples. However, certain noisy can be contained in the negative set, as false negative samples are possibly existed. Hence, the performance of the classifiers is not as accurate as they could be due to the biased prediction results. In this work, unknown substrate sites are regarded as unlabeled samples instead of negative ones. We propose a novel positive-unlabeled learning algorithm, namely PU-HIV, for an effective prediction of HIV-1 protease cleavage sites. Features used by PU-HIV are encoded from different perspectives of substrate sequences, including amino acid identities, coevolutionary patterns and chemical properties. By adjusting the weights of errors generated by positive and unlabeled samples, a biased support vector machine classifier can be built to complete the prediction task. In comparison with state-of-the-art prediction models, benchmarking experiments using cross-validation and independent tests demonstrated the superior performance of PU-HIV in terms of AUC, PR-AUC, and F-measure. Thus, with PU-HIV, it is possible to identify previously unknown, but physiologically existed substrate sites that are able to be cleaved by HIV-1 protease, thus providing valuable insights into designing novel HIV-1 protease inhibitors for HIV treatment.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Genet Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Genet Año: 2021 Tipo del documento: Article